MRKSo much for the fast lane
Merck is stepping back from plans to seek speedy approval for its lung cancer antibody-drug conjugate, ifinatamab deruxtecan, with Daiichi Sankyo. That’s a big pivot for a drug that had been part of the company’s next-wave oncology story.
Why investors care
This isn’t just paperwork getting shuffled around. A speedier filing can mean a quicker path to revenue, a cleaner storyline for the pipeline, and a fresh reason for Wall Street to squint at the growth runway. Pulling that plan takes some shine off the program — and probably takes a little air out of the “next big oncology win” balloon.
The bigger vibe
Merck has been juggling a lot of pipeline pieces lately, so this latest move adds to the sense that the company is still sorting out which assets get the red-carpet treatment and which ones get parked in the waiting lot.
Big picture: investors love a clean catalyst, and this one just got messier.